Liraglutide

First-generation daily GLP-1 with a long real-world safety record.

Typical dose range: 0.6–3.0 mg

Frequency: Daily

Route: Subcutaneous

Half-life: ~13 h

Evidence level: Strong (FDA-approved)

Overview

Sold as Victoza and Saxenda. Largely overshadowed by semaglutide and tirzepatide but still relevant where weekly dosing isn't tolerated.